Oklahoma Senate Bill SB426

Oklahoma 2026 Regular Session

• Introduced: 2/3/25
• Refer: 2/4/25

Caption

Practice of pharmacy; designating certain drugs as over-the-counter; prohibiting pharmacist or pharmacy from requiring prescription; providing penalties. Effective date.

Summary

SB 426 would classify chloroquine, hydroxychloroquine, and ivermectin as over-the-counter drugs in Oklahoma. Under the bill, pharmacists and pharmacies would be prohibited from requiring a prescription for these medications, meaning consumers could purchase them without first obtaining a doctor’s order. The bill also creates a strong enforcement mechanism. If the State Board of Pharmacy determines that a pharmacist or pharmacy violated the new rule, the Board would be required to immediately revoke the pharmacist’s or pharmacy’s license and impose a $100,000 fine for each violation. The act would take effect November 1, 2025.

Impact

SB 426 would add a new section to Title 59 of the Oklahoma Statutes governing pharmacy practice and drug dispensing. It would override ordinary prescription requirements for the three named drugs by making them legally available over the counter in Oklahoma, and it would expose pharmacists and pharmacies to mandatory license revocation and substantial civil penalties for noncompliance. The bill would directly affect pharmacies, pharmacists, the State Board of Pharmacy, and consumers seeking access to these medications.

Sentiment

No committee transcript or vote record is available in the provided materials, so there is no recorded debate or formal vote history to gauge legislative sentiment. Based on the bill text alone, the measure appears to reflect a strong policy preference for expanded access to the listed drugs and a punitive enforcement approach toward any pharmacy that continues to require prescriptions.

Contention

The main point of contention is likely the bill’s decision to make chloroquine, hydroxychloroquine, and ivermectin available without a prescription, which could raise concerns about patient safety, appropriate medical oversight, and off-label or controversial use. Another likely source of disagreement is the severity of the penalties: immediate license revocation and a $100,000 fine per occurrence are unusually harsh and could be viewed as excessive by pharmacists, regulators, or public health advocates. Supporters would likely emphasize access and consumer choice, while opponents would likely focus on professional standards and safety.